IPN

Ibotta Reports First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 30, 2024
Partnership, Workplace, The Denver Post, CPG, Income tax, Schnucks, Ibotta, Bank statement, Digital, Sale, IPN, Family Dollar, Research, Depreciation, GAAP, Table, Software, Adjustment, Bank

DENVER, May 30, 2024 (GLOBE NEWSWIRE) -- Ibotta, Inc. (NYSE: IBTA), a leading technology company providing digital promotions and performance marketing solutions, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The multi-year agreement, in which Ibotta is the exclusive provider of digital promotions, expands the array of offer types Ibotta supports to include digital coupons.
  • Subsequent to the quarter-end, Ibotta and Schnuck Markets Inc. (Schnucks) agreed to partner together to bring Schnucks’ customers savings on their groceries.
  • Earlier this month, Ibotta was named a Top Workplace by The Denver Post, ranking third in the large company category in Colorado.
  • Ibotta’s second quarter 2024 outlook is as follows:
    Revenue of $83.5 - $86.5 million, a year-over-year increase of 25% at the midpoint on a non-GAAP basis excluding the breakage benefit during the second quarter 2023.

Schnucks to Join Ibotta Performance Network, Collaborate with Ibotta to Reimagine the Future of Grocery Shopping for Consumers

Retrieved on: 
tisdag, maj 21, 2024
Partnership, Digital, IPN

In addition to Ibotta providing customers access to exclusive product offers in Schnucks’ stores throughout the Midwest, a key component of the partnership will be strategic R&D with the goal of building the next-generation grocery shopping experience for consumers.

Key Points: 
  • In addition to Ibotta providing customers access to exclusive product offers in Schnucks’ stores throughout the Midwest, a key component of the partnership will be strategic R&D with the goal of building the next-generation grocery shopping experience for consumers.
  • “Schnucks’ and Ibotta’s mutual track record of industry-leading innovation is a befitting foundation for our partnership to reimagine the grocery shopping experience of the future.
  • Together, we’ll collaborate to develop a more personalized, premium shopping experience for Schnucks customers.”
    The R&D component of the partnership will allow Ibotta and Schnucks to co-develop new customer experiences for a more dynamic grocery shopping journey.
  • Together with Ibotta, Schnucks is committed to creating innovative retail solutions that will shape the future of grocery shopping.”
    Digital offers from the IPN are set to become available to Schnucks customers later this year.

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Retrieved on: 
måndag, april 22, 2024
RNA, Partnership, Disease, Skyhawk, SVP, ADR, Research and development, Patient, DSM-IV codes, IPN

Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disorders

Key Points: 
  • Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disorders
    This promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets with small molecules, expanding the disease target landscape1
    PARIS, FRANCE; BOSTON, U.S., 22 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
  • The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC).
  • Following successful DC nomination, Ipsen will be responsible for all activities.
  • Skyhawk’s unique platform accelerates building RNA-targeting small molecules across several therapeutic areas, including rare neurological diseases.2
    “We are delighted to join forces with the expert teams at Skyhawk, as we explore the potential for modifying RNA expression across rare and debilitating neurological conditions.” said Steve Glyman, SVP and Head of Neuroscience, Research & Development at Ipsen.

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Retrieved on: 
måndag, april 22, 2024
Ipsen, RNA, Partnership, Research, Disease, Skyhawk, Therapy, SVP, ADR, Research and development, Patient, DSM-IV codes, IPN

The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC).

Key Points: 
  • The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC).
  • Skyhawk's unique platform accelerates building RNA-targeting small molecules across several therapeutic areas, including rare neurological diseases.2
    "We are delighted to join forces with the expert teams at Skyhawk, as we explore the potential for modifying RNA expression across rare and debilitating neurological conditions."
  • said Steve Glyman, SVP and Head of Neuroscience, Research & Development at Ipsen.
  • "Our strategic partnership underscores our shared ambition to develop transformative medicines for people with rare neurological diseases for which there are no approved therapeutics."

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Retrieved on: 
måndag, april 22, 2024
Ipsen, RNA, Partnership, Research, Disease, Skyhawk, Therapy, SVP, ADR, Research and development, Patient, DSM-IV codes, IPN

The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC).

Key Points: 
  • The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC).
  • Skyhawk's unique platform accelerates building RNA-targeting small molecules across several therapeutic areas, including rare neurological diseases.2
    "We are delighted to join forces with the expert teams at Skyhawk, as we explore the potential for modifying RNA expression across rare and debilitating neurological conditions."
  • said Steve Glyman, SVP and Head of Neuroscience, Research & Development at Ipsen.
  • "Our strategic partnership underscores our shared ambition to develop transformative medicines for people with rare neurological diseases for which there are no approved therapeutics."

What does new micro price evidence tell us about inflation dynamics and monetary policy transmission?

Retrieved on: 
torsdag, april 25, 2024
Online, Sun, High, Quarterly Journal of Economics, Printing, Inflation, Data set, PRISMA, Journal of Political Economy, Research, Euro, Business, ECB, Shock, Quarterly Journal, Policy, IPN, Section 4, Bank of Lithuania, Journal, Bank of France, Human, Journal of Monetary Economics, Textbook, Food, American Economic Journal, Business cycle, Princeton University Press, Element, Consumer, CPI, Forecasting, Growth, Environment, Political economy, Monetary economics, Bank, Rest, Mistake, HICP, Price, Heart, Daily, Geography, Data, Collection, Probability, Supermarket, Retail

To understand inflation dynamics, it is necessary to analyse how often and by how much individual prices change.

Key Points: 
  • To understand inflation dynamics, it is necessary to analyse how often and by how much individual prices change.
  • This article discusses what micro price data gathered by the European System of Central Banks’ Price-setting Microdata Analysis Network (PRISMA) tell us about the way firms set their prices.

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Retrieved on: 
tisdag, april 2, 2024
ADR, Patient, SAN, SVP, Research, STRO, Cancer, IPN, Spacecraft, IND, Investigational New Drug, Development, ADC, Medicine

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development

Key Points: 
  • Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development
    PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003.
  • “The potential for ADCs in oncology is well-documented and we are excited by the addition of STRO-003, Ipsen’s first ADC candidate with best-in-class potential.” said Mary Jane Hinrichs, SVP and Head of Early Development at Ipsen.
  • “STRO-003 is a next-generation ROR1 ADC, leveraging Sutro’s site-specific technology to generate a highly stable conjugate, coupled with exatecan payloads, that have shown significant potential in solid tumors.
  • Payloads are the pharmaceutically active component to treat the cancer, attached to the antibody via a chemical linker.

Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen

Retrieved on: 
tisdag, april 2, 2024
Partnership, ADR, Patient, Research, Cancer, STAR, IPN, IND, MBA, TCR, Vaccine

This clinical candidate reflects a productive collaboration since the strategic partnership was signed in August 2022 .

Key Points: 
  • This clinical candidate reflects a productive collaboration since the strategic partnership was signed in August 2022 .
  • Marengo and Ipsen plan to advance the program through IND-enabling studies and into clinical development.
  • This nomination represents the first of two selective T cell activation repertoire (STAR) T cell bi-functional activator programs that Marengo and Ipsen will advance as part of the collaboration.
  • Marengo is leading the research and preclinical development efforts while Ipsen will assume responsibilities for regulatory submissions, clinical development and commercialization.

Family Dollar Teams Up with Ibotta to Create Next Generation Digital Offer Program

Retrieved on: 
torsdag, mars 7, 2024
Love, DLTR, IPN, Family, Family Dollar, Partnership, Retail

The partnership aims to advance Family Dollar’s digital engagement and customer experience strategy to drive more value and loyalty among its customers.

Key Points: 
  • The partnership aims to advance Family Dollar’s digital engagement and customer experience strategy to drive more value and loyalty among its customers.
  • By partnering with Ibotta, Family Dollar customers will benefit from access to more, new national offers, increased flexibility for digital rewards and an improved shopping experience.
  • Ibotta's promotions platform will power digital coupons through Family Dollar's website and mobile app Smart Coupons program, delivering incremental savings to all Family Dollar customers.
  • The Family Dollar app is part of the digital transformation occurring at the company, with improvements to the app making shopping easier and even more enjoyable.

Ibotta Expands Senior Leadership Team, Adds Seasoned CLO David Shapiro

Retrieved on: 
måndag, februari 19, 2024
IA Financial Group, IPN, Risk management, CPG, Sale, Government, General counsel, Ibotta

DENVER, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Ibotta , a leading technology company providing digital promotions and performance marketing solutions, has hired seasoned legal, compliance, and strategy leader David Shapiro as the company’s first Chief Legal Officer.

Key Points: 
  • DENVER, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Ibotta , a leading technology company providing digital promotions and performance marketing solutions, has hired seasoned legal, compliance, and strategy leader David Shapiro as the company’s first Chief Legal Officer.
  • Shapiro will join Ibotta’s Senior Leadership Team and oversee all legal, risk management, and corporate governance activities.
  • “I have known David personally for several years, and I am thrilled to welcome him to our leadership team.”
    David most recently served as Executive Vice President and General Counsel at Vail Resorts.
  • “I am very excited about this incredible opportunity and honored to join this innovative and forward-thinking organization,” Shapiro said.